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The allogeneic therapeutic vaccine CSF-470 has demonstrated a significant benefit 
over medium-dose IFNα2b in the distant metastasis-free survival for stages IIB–IIC–III 
cutaneous melanoma patients in a randomized phase II/III clinical trial (CASVAC-0401, 
NCT01729663). At the end of the 2-year CSF-470 immunization protocol, patient #006 
developed several lung and one subcutaneous melanoma metastases; this later was 
excised. In this report, we analyzed the changes throughout vaccination of immune 
populations in blood and in the tumor tissue, with special focus on the T-cell repertoire. 
Immunohistochemistry revealed a marked increase in CD8+, CD4+, and CD20+ lympho-
cytes infiltrating the metastasis relative to the primary tumor. Lymphocytes were firmly 
attached to dying-tumor cells containing Granzyme-B granules. Whole-exon sequencing 
assessment indicated a moderate-to-high tumor mutational burden, with BRAFV600E as 
the main oncogenic driver. Mutational signature presented large numbers of mutations at 
dipyrimidines, typical of melanoma. Relevant tumor and immune-related genes from the 
subcutaneous metastasis were addressed by RNA-Seq analysis, revealing expression 
of typical melanoma antigens and proliferative tumor-related genes. Stimulatory and 
inhibitory immune transcripts were detected as well as evidence of active T-cell effector 
function. Peripheral blood monitoring revealed an increase in CD4+ and CD8+ cells by 
the end of the immunization protocol. By CDR3-T-cell receptor β (TCRβ) sequencing, 
generation of new clones and an increase in oligoclonality was observed in the peripheral 
T-cells immune repertoire throughout immunization. A shift, with the expansion of selected 
preexisting and newly arising clones with reduction of others, was detected in blood. In 
tumor-infiltrating lymphocytes, prevalent clones (50%) were both new and preexisting 
that were expanded in blood following CSF-470 immunization. These clones persisted 
in time, since 2 years after completing the immunization, 51% of the clones present in 
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the metastasis were still detected in blood. This is the first report of the modulation of the 
TCRβ repertoire from a melanoma patient immunized with the CSF-470 vaccine. After 
immunization, the changes observed in peripheral immune populations as well as in the 
tumor compartment suggest that the vaccine can induce an antitumor adaptive immune 
repertoire that can reach tumor lesions and persists in blood for at least 2 years.
Keywords: cutaneous melanoma, CsF-470 vaccine, t-cell receptor β immune repertoire, cancer immunogram, 
tumor immune infiltration
INtRoDUCtIoN
Our group has developed the therapeutic vaccine CSF-470, 
an allogeneic mixture of four-lethally irradiated cutane-
ous melanoma (CM) cell lines co-adjuvated with bacillus 
Calmette–Guerin (BCG) and recombinant human granulocyte 
macrophage colony-stimulating factor (rhGM-CSF), for the 
adjuvant treatment of stages IIB–IIC–III CM patients. Recently, 
in a randomized phase II study, CSF-470 vaccine has demon-
strated a significant benefit in distant metastasis-free survival 
versus interferon alpha 2b (IFNα2b), with good tolerability and 
evidence of induction of adaptive and innate immune responses 
(1). Assessment of the mechanisms leading to clinical benefit 
in adjuvancy is challenging, and monitoring different aspects 
of the tumor–immune system axis can be of vital importance. 
Along with this line, a cancer immunogram recently proposed 
by Blank et al. aims to analyze multifactorial aspects related to 
tumor immunotherapy, with focus on T  cell function, includ-
ing tumor foreignness, general immune status, immune cell 
infiltration, presence of immune checkpoints (ICKs) and other 
inhibitory molecules, and sensitivity to immune effectors (2). 
Furthermore, integral exomic and transcriptomic analysis of 
non-microdissected metastatic melanoma tissues allows deter-
mining tumor mutations and expression of genes related to 
tumor biology and immune status, which can have an impact on 
patient’s outcome. Recently, the usefulness of targeted RNA-Seq 
in profiling a panel of immune transcripts has been proposed to 
measure the abundance of immune transcripts in tumor biopsies 
to develop a gene-expression profile instrument to predict clini-
cal response to immunotherapy (3).
In this work, we present the analysis of samples obtained from 
a CM patient treated with the CSF-470 vaccine (CASVAC-0401 
study) who developed metastases at the end of the 2-year immu-
nization treatment, among them a subcutaneous metastasis 
(SC mts) which was resected. This case allowed us to study the 
local immune resp onse and its relationship with changes in the 
peripheral blood immune response during 4 years of follow-up 
(F-UP). We characterized tumor-driver genes and immune profile 
oriented gene-expression pattern in the SC mts; dynamics of the 
blood immune response throughout the vaccination protocol was 
also followed by analysis of the T-cell receptor β (TCRβ) immune 
repertoire.
Case RepoRt
patient’s #006 Case presentation  
and treatment
In October 2010, patient #006, a 50-year-old Caucasian woman, 
had a primary CM resected from her back. Three months later, 
an axillary sentinel lymph node with micrometastasis was 
excised (January 2011) (Figure  1A). After a radical axillary 
lymph node resection, 0/18 metastatic lymph nodes were found. 
In June 2011, the patient signed informed consent and entered 
the CASVAC-0401 study, being assigned to the CSF-470 arm. 
CASVAC-0401 is a single institution, randomized, open-label 
phase II/III study, to investigate in CM pts stages IIB, IIC, and 
III post-surgery (adjuvancy) the efficacy and safety (primary 
objectives) as well as the quality of life and immune response 
(secondary objectives) of the CSF-470 vaccine versus medium-
dose IFN-α2b treatment (ClinicalTrials.gov: NCT01729663). 
Vaccine CSF-470 is an allogeneic vaccine consisting of irradi-
ated CM cell lines plus BCG and rhGM-CSF; immunization 
protocol was followed as described (1). Two years later, at the 
end of the 13-vaccine immunization program, the patient devel-
oped SC and lung metastases; the SC mts was resected (June 
2013); a part of the biopsy was formalin-fixed and paraffin-
embedded for histological analyses, and a part was preserved 
at −80°C in RNAlater (Ambion). Bilateral lung nodules of up 
to 1-cm diameter were detected by a CT scan. Since this tumor 
had the BRAFV600E mutation, the patient started treatment 
with Vemurafenib 960 mg bid on December 2013, achieving a 
complete response within 3 months of treatment. This patient 
remained stable up to December 2016, when she developed 
lung, bone, and brain mts for which she received holocraneal 
radiotherapy. The last contact was on June 2017, and the patient 
was still alive.
Immune assessment of tumor tissues
The primary tumor in the back was a nodular, epithelioid 
CM with 3.0  mm Breslow thickness, micro-ulceration, vessel 
infiltration by tumor cells, and 15% Ki-67+ tumor proliferating 
cells (Figure S1I in Supplementary Material). The SC mts that 
developed in the patient’s back, in the vicinity of the previous scar, 
had defined expansive edges, with areas of epithelioid tumor cells 
Abbreviations: Abs, antibodies; Ags, antigens; BCG, bacillus Calmette–Guerin; 
CM, cutaneous melanoma; DCs, dendritic cells; FFPE, formalin-fixed and paraf-
fin-embedded; FPKM, fragments per kilobase of exon per million reads mapped; 
F-UP, follow-up; GZMB, Granzyme B; HLA, human leucocyte antigen; ICKB, 
immune checkpoint blockade; ICKs, immune checkpoints; Igs, immunoglobulins; 
pts, patients; PBMC, peripheral blood mononuclear cells; PI, proliferative index; 
QOL, quality of life; rhGM-CSF, recombinant human granulocyte-macrophage 
colony-stimulating factor.
FIGURe 1 | Patient #006 timeline and immune infiltrate analysis in post-vaccination subcutaneous metastasis (SC mts). (a) The patient was randomized to the 
CSF-470 vaccine arm of CASVAC-0401 study. Tumor resections of primary tumor, sentinel node, and SC mts are indicated by triangles. Peripheral blood 
mononuclear cell (PBMC) samples were obtained at 0 (PBMC-PRE), 6 (PBMC-POST-1), 12 (PBMC-POST-2), 24 (PBMC-POST-3), and 48 months (PBMC-POST-4) 
from vaccine protocol. *Lung and SC mts were detected at the same time; tumor-infiltrating lymphocytes (TIL) were obtained from the SC mts. Samples selected for 
T-cell receptor β sequencing are indicated with red triangles and in italics. (B) Representative pictures of the same region in the SC mts after IHC staining for CD8, 
Granzyme-B (GZMB), in situ nick translation (ISNT), CD4, PD-1, and PD-L1 are shown (DAB, brown). Insets show positive staining under high magnification 
(1,000×). Scale bars = 100 µm.
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adjoined by zones of dense fibrosis and zones fulfilled with brisk 
lymphocyte infiltration (Figure S1II in Supplementary Material). 
A decreasing proliferative index (PI) from 40% Ki-67+ tumor 
cells in areas without lymphocytic infiltration, to 15% Ki-67+ in 
highly infiltrated zones was observed. Ki-67+ lymphocytes were 
also distinguished (not shown). In the areas of brisk lymphocyte 
infiltration, necrotic/apoptotic tumor cells, distinguished by cell 
shrinkage with nuclear disruption, were observed surrounded 
by immune cells, mainly CD8+ and CD4+, some of them firmly 
attached (Figure  1B); Granzyme-B staining revealed positive 
cytosolic granules in tumor cells. In situ nick translation (ISNT) 
detected positive nuclei and vesicles within dying-tumor cells, 
confirming the presence of apoptotic tumor cells in close contact 
with lymphocytes (Figure  1B). Few PD-1+ lymphocytes were 
observed attached to tumor cells, PD-L1 expression was negative 
(Figure 1B). Also, CD45Ro+ and CD68+ cells were seen in the 
same areas (data not shown).
Comparative analysis of the immune cells infiltrating the 
primary tumor and the SC mts revealed an increase mainly of 
CD8+, CD4+, and CD20+ lymphocytes (Figure  2A). Total cell 
counts across whole tumor sections were performed to determine 
immune-to-tumor cell ratio; CD8+, CD4+, and CD20+ lympho-
cytes increased 10-fold, 3-fold, and 2-fold, respectively, in the SC 
mts with respect to the primary tumor, while Foxp3+ cells were 
scarce (Figure 2B). CD11c+ and CD68+ antigen (Ag)-presenting 
cells were also frequently detected; CD45Ro+ memory cells 
decreased at the SC mts (Figure  2B). NKp46+ cells (NK  cells) 
were scarce and distributed in the periphery of the SC mts (data 
not shown).
Immune assessment of pBMC samples
Peripheral blood lymphocyte analyses revealed a sustained 
increase in total lymphocytes, and of T CD4+, T CD8+, and 
NK  cells during CSF-470 treatment (Figure  2C). Whereas the 
FIGURe 2 | Immune profiling of patient #006. (a) Representative pictures of the primary tumor and subcutaneous metastasis biopsies infiltrated by CD8+, CD4+, 
CD20+, and Foxp3 lymphocytes determined by IHC (DAB, brown). (B) After counting total biopsy area, immune-to-tumor cell ratios were determined for each tumor 
biopsy as well as the relative ratio between primary tumor and SC metastasis (1). (C) Absolute counts of total lymphocytes, T CD4+, T CD8+, Treg, and NK cells from 
PBMC were determined throughout CASVAC-0401 treatment and follow-up by flow cytometry; also, absolute counts of lymphocytes (Ly) and neutrophils (Neu) are 
shown (D). Scale bars = 50 µm.
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marked increase in NK cells was already detected 6 months fol-
lowing the first immunization, CD4+ and CD8+ T cells increased 
by the end of the protocol (24 months); low and stable levels of 
Tregs were observed throughout treatment (Figure 2C). Two years 
after completing the immunization protocol, CD4+ increased 
while CD8+ levels decreased, although remaining at higher levels 
than at baseline; NK and Tregs stayed still (Figure 2C). Also, an 
increase in serum immunoglobulin G Abs recognizing both CSF-
470 cells as well as patient’s autologous tumor cells was reported 
elsewhere (1). Neutrophils/lymphocytes ratio sharply diminished 
during CSF-470 immunization (Figure 2D).
tumor Mutational Burden and Gene-
expression analysis of sC mts
Patient #006 SC mts was highly mutated. After elimination of 
germline variants, somatic mutations revealed a total number 
of 712 SNPs and 33 InDels. We found 239 mutations in coding 
sequences: 7 were insertions; 72 were synonymous variants, 
and 156 were missense mutations. Tumor mutational burden 
was moderate to high (TMB = 745 variants/50.39 Mb = 14.8), 
suggesting that immunogenic neoantigens might have been 
generated. Among driver genes, BRAFV600E, FBXW7S608T, and 
CICΔ374 heterozygous mutations were found. Analysis of muta-
tional signature revealed fingerprints related to failure of DNA 
double-strand break-repair by homologous recombination; large 
numbers of CC>TT dinucleotide mutations at dipyrimidines 
due to ultraviolet light exposure, typical of melanoma, were also 
found (Figure S2 in Supplementary Material).
RNA-Seq of the SC mts revealed the expression of several 
melanoma-associated Ags, many of them shared with the 
CSF-470 vaccine cells (Table  1) (1). Also, typical melanoma 
markers, such as MC1R, vimentin, MITF, CD63, and LADH 
were abundant (Table  1). Since the whole tissue biopsy was 
sequenced, containing both tumor and brisk immune cells infil-
tration, we focused on transcripts that could reflect the immune 
expression profile of the tumor microenvironment. Human 
leucocyte antigen (HLA) class I (HLA-A) and β2M transcripts 
taBLe 1 | Abundance of selected immune-related transcripts from subcutaneous metastasis from patient #006.
associated gene name FpKM associated gene name FpKM associated gene name FpKM
Melanoma markers tCR co-expression and signaling Human leucocyte antigen (HLa) 
expression
CD63 3,487.90 CD3D 51.37 HLA-A 890.74
Vimentine 2,928.7 CD8B 14.82 HLA-DRB4 195.09
CTSD 408.69 CD3E 11.16 HLA-B 118.11
CDK4 268.04 CD8A 7.47 HLA-DRA 94.56
LDHA 227.53 LCK 7.40 HLA-DRB3 81.38
SPARC 189.08 CD3G 1.71 HLA-DRB1 34.71
MITF 20.21 NFKBIA 31.67 HLA-C 2.55
MC1R 9.82 PTPN6 10.73
VEGFA 3.38 ZAP70 6.67
CBLB 1.55
Melanoma differentiation antigens Cytokines and chemokines Immune checkpoints and  
ligands
PMEL/gp100 528.89 CXCL1 24.48 PD-1 1.84
MLANA/MART-1 289.90 CXCL10 23.69 CD274/PD-L1 (PD-1) 0.81
TYR 63.37 CXCL9 16.14 PDL2 (PD-1) 1.74
RAB38 (NY-MEL-1) 33.46 CSF1R 13.12 CTLA4 1.82
DCT/TRP2 30.33 CXCL8 4.68 CD80 (CTLA4) 0.57
TNF 1.51 CD86 (CTLA4) 5.95
IFNGR2 65.96 TIM-3 6.70
IFNGR1 19.59 LSGAL9 (TIM-3) 37.83
CD40 12.74
CD40LG (CD40) 0.29
ICOS 0.91
ICOSLG (ICOS) 1.48
Cancer testis antigens Immunosuppressive molecules Cytolytic activity
MAGED2 289.16 LGALS1 4,643.39 GZMA 26.61
GPR143 125.40 LGALS3 2,165.00 GZMK 24.73
MAGED1 71.97 HLA-E 536.57 GZMB 14.79
IL13RA2 2.72 TGFB1 21.45 GNLY 14.35
SPAG9 1.98 IDO1 13.05 GZMH 11.50
IL-10 0.39 PRF1 4.35
Abundance of selected transcripts is expressed in fragments per kilobase of exon per million reads mapped (FPKM).
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were abundantly expressed (Table 1). Stimulatory ICKs such as 
CD40, as well as inhibitory ICKs such as CTLA4, B7-H3, TIGIT, 
Tim-3, and LAG-3 were detected. PD-1/PD-L1 transcripts were 
scarce. Immunosuppressive molecules IDO, galectins 1, 3, and 9, 
and HLA-E were expressed, but no IL-10 was detected. Markers 
of inflammation such as TNF-α, CSF1R, and CXCL8 were also 
abundant. We also searched in our RNA-Seq results for a panel of 
transcripts related to T-cell receptor signaling, tumor infiltration 
by immune cells, and other immunological functions that are 
key for anticancer immunosurveillance (3). We found elevated 
expression of leukocyte population markers; Ag processing and 
presenting genes; and IFN-I and II response genes. Finally, tran-
scripts of CD4+ and CD8+ T cells markers, TCR co-expression 
and receptor signaling, and granzyme and perforin genes were 
abundantly detected (Table S1 in Supplementary Material).
Diversity of the tCRβ Immune Repertoire 
in Blood and sC mts
An increase in CD4+ and CD8+ lymphocytes in the peripheral 
compartment after immunization with the CSF-470 vaccine, as 
well as a brisk infiltration of CD4+ and CD8+ lymphocytes in the 
SC mts, was observed (Figure 2A). We analyzed the dynamics 
of the T-cell repertoire throughout immunization with the CSF-
470 vaccine, since a central question was whether TIL clones 
were already present in blood previous to CSF-470 immuniza-
tion, which expanded and were recruited to the SC mts; or if 
new T-cell clones arose after immunization. We performed NGS 
of the CDR3 region of the TCRβ repertoire genes, since within 
the TCR, this region contains the highest variability, making 
it a suitable molecular identifier for tracking individual T-cell 
clones (4). TCRβ sequence analyses were performed in the SC 
mts TIL and in PBMC samples obtained before (PBMC-PRE), 
during CSF-470 immunization (PBMC-POST-1 and PBMC-
POST-3), and 2  years after completing the vaccine protocol 
(PBMC-POST-4) (Figure  1A; Tables S2–S6 in Supplementary 
Material).
To describe the diversity of the TCRβ immune repertoire of 
each sample, considering the number of unique receptors (rich-
ness) and their relative abundances (evenness), different analyses 
were performed. Analyses of the 100 most frequent TCRβ clones 
(TOP100) indicated an increment in their cumulative frequency 
throughout immunization, supporting preferential expansion of 
a subpopulation of T-cell clones (Figure 3A). TOP100 TIL clones 
FIGURe 3 | Distribution and tracking of the T-cell receptor β (TCRβ) immune repertoire in peripheral blood mononuclear cells (PBMC) and subcutaneous metastasis 
from patient #006. (a) Percentage of total TCRβ clones covered by the TOP100 clones, the 100 most frequent ones (nucleotide sequences). (B) Total TCRβ clones 
(%), from highest to lowest, in function of their cumulative frequency (nucleotide sequences). (C) The proportion of TCRβ clones (%) that constitute the TOP-25 or 
TQ clones, and the TOP-50 clones are shown (TOP-25/50, the proportion of clones that make up the top cumulative frequency of 25/50). (D) Pattern distribution of 
TCRβ clones in total PBMC, total tumor-infiltrating lymphocytes (TIL), and Top-Quartile TIL (TQ-TIL); the number of clones for each pattern and total clones analyzed 
in each case is indicated. Patterns: 1, present at baseline, increases in time; 2, absent at baseline, increases in time; 3, absent at baseline, detected at POST-3 
sample; 4, present at baseline, decreases in time; 5, present at baseline, absent in time; and 6, absent at blood, present in tumor. (e) Common sequences among 
PBMC-PRE, PBMC-P1, PBMC-P3, and TIL samples. (F) The proportion of TIL clones present in blood at different times. (G) Venn diagram illustrating common 
clones among TIL and POST-4 samples regarding amino acid sequences. (H) Distribution in tracking patterns of total and TQ-TIL clones shared with PBMC 
POST-4. Pattern 3: absent at baseline, detected at POST-4 sample.
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from the SC mts showed an oligoclonal TCRβ repertoire almost 
attaining the top-quartile most frequent clones (TQ) (Figure 3A). 
Also, the frequency of each TCRβ clone in the immune repertoire 
(%), ordered from highest to lowest, was plotted in function of its 
cumulative frequency (%) to compare blood samples (Figure 3B). 
PBMC-PRE sample presented a linear pattern, which is related to 
an homogeneous distribution of the TCRβ repertoire. A similar 
pattern was observed for PBMC-POST-1. Instead, a sigmoideal 
pattern was observed for PBMC-POST-3 sample, as less T-cell 
clones make up more of the entire repertoire. Thus, there was 
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a progressive enrichment in a subset of T-cell clones. A similar 
pattern was observed for PBMC-POST-4 (Figure 3B). When ana-
lyzing the proportion of clones that make up the top cumulative 
frequency of 25 [TOP-25 or Top-Quartile (TQ)] or 50 (TOP-50), 
it decreases over time; further supporting the expansion of a 
subpopulation of T-cell clones (Figure 3C).
Dynamics of the tCRβ Immune Repertoire 
throughout Immunization With the CsF-
470 Vaccine
To further analyze the changes induced in the TCRβ immune 
repertoire of patient #006 throughout immunization with the 
CSF-470 vaccine, six different patterns for tracking T-cell clones 
in blood were defined (Figure 3D; Figure S3A in Supplementary 
Material). A shift in the TCRβ repertoire composition in blood 
was observed, with a significant proportion of pre-existing clones 
increasing its frequency (pattern 1) or newly arising throughout 
immunization at 12 and 48  months (pattern 2 and pattern 3). 
Opposite to that, a proportion of clones either decreased (pat-
tern 4) or became undetectable by the end of the immunization 
protocol (pattern 5).
Characterization of the tCRβ Immune 
Repertoire Infiltrating the sC mts
Analysis of shared amino acid sequences among TIL and blood 
samples revealed that all samples shared 10% of the clones, and 
16% were shared by TIL and PBMC-POST3 (Figure 3E). When 
total TIL clones were analyzed considering the tracking patterns 
for peripheral clones, 53% of TIL clones were only detected at the 
tumor microenvironment (pattern 6); 13.6% corresponded to pre-
existing clones that expanded during immunization (pattern 1), 
clones emerging during immunization and detected at 12 months 
(2.2%, pattern 2) and 24 months by the end of immunization (15.9%, 
pattern 3) (Figure  3D). 9.3 and 6.0% of TIL clones diminished 
their frequency in blood or were no longer detected. When looking 
at the most frequent Top-Quartile TIL clones (TQ-TIL), preexist-
ing clones (pre-vaccination) were enriched (pattern 1, 31.6%), 
prevailing along with late-emerging clones (pattern 3, 19.8%) 
(Figure  3D). 58% of TQ-TIL clones corresponded to pattern 1 
clones that have expanded in blood at least three times; and 45% of 
TQ-TIL clones were in the 2.4% most abundant clones in PBMC-
POST-3 sample (pattern 3) (data not shown). This supports the 
idea that a considerable proportion of abundant TIL clones 
(TQ-TIL) are among those that were expanded in blood, either 
preexistent or emerging post-vaccination. TQ-TIL clones detected 
only at the tumor microenvironment accounted for 31.6% (pattern 
6) (Figure 3D).
A F-UP blood sample, obtained 2 years after patient #006 com-
pleted the protocol and after 2 years of intermittent treatment with 
vemurafenib (PBMC-POST-4 sample), revealed that TCRβ clones 
found in the tumor microenvironment could still be detected in cir-
culation. Indeed, the cumulative frequency of TIL clones detected 
in blood doubled from 5% (PBMC-PRE) to 10.7% total frequency 
(PBMC-POST-3) (Figure 3F). Two years later (PBMC-POST-4 
sample), TIL clones were still detected in blood with a cumulative 
frequency of 8.9% (Figure 3F). Actually, 51% of total TIL clones 
were shared with the POST-4 sample (Figure  3G). These 706 
common clones were distributed mainly in four patterns, 56% of 
them corresponded to patterns 1 and 2; while 21.6% were detected 
only at POST-4 blood sample (pattern 3) (Figure 3H; Figure S3 
in Supplementary Material). When looking at TQ-TIL clones 
shared with PBMC-POST-4, expanded preexisting and clones 
arising during immunization accounted for 70.8% (patterns 1 and 
2) (Figure 3H). These results suggest that CSF-470 vaccination in 
patient #006 modulated the repertoire of T-cell clones and their 
frequency, and that particularly those clones expanded during 
immunization persisted at least 24 months after the end of the 
vaccination protocol.
T  cells with shared Ag specificities should share conserved 
CDR3 structural domains and amino acid sequences, as they 
recognize the same epitopes (5). An oligoclonal pattern of Vβ 
expression should thus be observed if Ag-driven stimulation 
causes clonal expansion. We found that this patient presented a 
Vβ gene usage distribution that was mainly conserved in time 
in peripheral PBMC and TIL (Figure S4A in Supplementary 
Material). When analyzing total TIL, as well as TIL that persisted 
in time (PBMC-POST-4 ∩ TIL) according to their distribution 
patterns, the Vβ gene usage distribution was similar (Figures 
S4B,C in Supplementary Material).
DIsCUssIoN
We present here the analysis of samples from patient #006 
enrolled in the CASVAC-0401 trial treated with the CSF-470 
vaccine, who simultaneously developed one SC and several lung 
mts after receiving 13 immunizations during 2  years (1). The 
SC mts was excised and offered the opportunity to correlate the 
tumor and peripheral immune responses during immunization 
and 2-year F-UP. Immunohistochemical analysis of the SC mts 
revealed a 10-fold increase of CD8+ lymphocytes with respect 
to the primary tumor; less so (3-fold) for CD4+ cells. Evidence 
suggesting that CD8+, CD4+, and macrophages effector cells were 
actually killing tumor cells was obtained, supported by ISNT and 
GZMB expression. The reason why some tumor areas are infil-
trated whereas other parts of the tumor appear unreached is not 
known. It does not appear to be due to an unequal distribution 
of immune suppressor cells, since FOXP3+ Tregs were scarce and 
even macrophages appeared to be lysing tumor cells.
To elucidate if immune effector cells preexisted before vaccina-
tion and/or were triggered by it, we compared the TCRβ immune 
repertoire of blood and TIL. Peripheral blood monitoring revealed 
an increase in CD4+ and CD8+ cells by the end of the immunization 
protocol. Along vaccination, a shift in the peripheral CDR3-TCRβ 
immune repertoire, with the expansion of preexisting clones (2% 
of total clones), the appearance of new clones (50% of total), and 
diminution of others (45% of total), was observed. Although 
preexisting TCRβ clones might recognize private or melanoma-
associated Ags previous to vaccination, their expansion suggests 
a positive effect of vaccination. A central question, however, was 
if vaccination induced lymphocyte clones able to travel into the 
metastatic foci. Most important, analysis of TIL clones revealed 
that 29.5% of them were preexisting or late-emerging in blood. 
Therefore, vaccination induced the generation and expansion of 
8Aris et al. TCRβ Repertoire after CSF-470 Immunization
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T  cell clones that were able to migrate into tumor sites. When 
looking at the most frequent clones (TQ-TIL), which might be 
the more relevant for antitumor function (6), preexisting as well 
as late-emerging clones became prevalent, accounting for 51% 
of the total. The proportion of TIL clones present in the blood 
repertoire doubled in time throughout immunization, remaining 
at levels higher than detected at baseline. An F-UP blood sample, 
obtained 2  years after completing the immunization protocol, 
showed that half of TIL clones could still be detected; although it 
should be pointed that patient #006 was treated with vemurafenib 
for 21 months when the F-UP sample was taken (09/2015). The 
patient achieved a complete response to vemurafenib of 31 months 
duration, after which she progressed with lung, bone, and brain 
mts. There is evidence that vemurafenib does not interfere with 
the viability or functionality of T cells (7, 8). In this case, we could 
still detect TCRβ TIL clones 2 years after completing immuniza-
tion with the CSF-470 vaccine; conceivably, further Ag-input 
was delivered to the immune system due to tumor cell lysis as 
suggested by the clinical complete response to vemurafenib. The 
correlate of the findings in the SC mts with the lung mts could 
not be performed to determine if a similar immune reaction 
was taking place. It is nevertheless remarkable that the patient 
achieved a complete response with vemurafenib for more than 
2 years, although the relationship between this response and the 
immune reaction may not be ascertained.
In line with our findings, Valmori et al. reported a functional 
and structural longitudinal analysis of the TCR of circulating 
CD8 T cells specific for the HLA-A2-restricted immunodominant 
epitope from the melanocyte differentiation Ag Melan-A in a mela-
noma patient who developed a vigorous and sustained Ag-specific 
T  cell response following vaccination with the corresponding 
synthetic peptide. Some of these T cell clones were also identified at 
a metastatic tumor site, concluding that vaccine stimulation leads 
to the selection of high-avidity T cell clones of increased tumor 
reactivity that independently evolve within oligoclonal populations 
(9). Also, Carreno et al. reported that immunization with a den-
dritic cell-based personalized vaccine targeting neoantigens and 
gp100 peptides in three melanoma patients, promoted a diverse 
neoantigen-specific T  cell receptor repertoire in terms of both 
TCRVβ usage and clonal composition. In pre-vaccination CD8+ 
T cell populations, as few as one and as many as 10 unique TCRβ 
clonotypes per neoantigen were identified. Vaccination increased 
the frequency of most existing pre-vaccine TCRβ clonotypes 
and revealed new clonotypes for all neoantigens tested. For both 
dominant and subdominant neoantigens, the TCRβ repertoire was 
increased significantly after vaccination (10).
Integral analysis of a non-microdissected metastatic melanoma 
tissue allowed us to carry out an exploratory search for expression 
of genes related to tumor biology and to the presence of immune 
populations infiltrating the tumor. Immunohistochemistry and 
RNA-Seq results suggest that immunization with CSF-470 vaccine 
has triggered T-cell priming, as seen by brisk tumor immune infil-
tration. Other inhibitory immune pathways might be activated, as 
suggested by the abundance of B7-H3 and galectin 1 (11), galectin 
3 (12), and galectin 9 transcripts (13, 14). Also, Tim-3 and LAG-3 
transcripts were detected; expression of these exhaustion molecules 
was previously reported in tumor-reactive infiltrating lymphocytes 
following PD-1 immune checkpoint blockade (ICKB) (15). Only 
a low proportion of TIL expressed PD-1, probably preexisting 
Ag-experienced T cells, some of them in contact with tumor dying 
cells. Low levels of PD-1+ expression found in TIL can be due to 
the fact that PD-1 is transiently expressed in T cells activation by 
Ags (16). Since high PD-1 expression levels are achieved in chronic 
microenvironments, probably this inflamed tumor was removed 
before the establishment of local immune escape mechanisms 
driven by chronic tumor Ag exposure (17). Also, high levels of 
LADH were detected, indicative of a highly proliferative tumor, 
supported by Ki-67+ PI and activation of MAPK pathway through 
BRAF mutation. Along with this line, a recent work on a cohort 
of metastatic CM patients reported that response to PD-1 ICKB 
was better predicted when integrating T cell invigoration to tumor 
burden. Many TCRβ clones detected in pre-treatment TIL were 
also detected in blood only after treatment thus supporting the 
induction of an immune response. The clinical outcome was better 
predicted when the ratio of re-activated exhausted T cells to tumor 
burden was taken into account (18).
CoNCLUDING ReMaRKs
This is the first report of the TCRβ repertoire from a CM patient 
immunized with the CSF-470 vaccine. The changes observed in 
peripheral immune populations as well as in the tumor compart-
ment after immunization suggest that the vaccine can induce 
an antitumor adaptive immune repertoire that can reach tumor 
lesions and persist in blood for at least 2 years.
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